Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study

• Published in: International journal of clinical oncology Vol. 29; no. 7; pp. 972 - 984
• Main Authors: Önder, T., Ateş, Ö., Öner, İ., Karaçin, C.
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.07.2024; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Aminopyridines - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer Research; Cyclin-dependent kinase 4; Cyclin-Dependent Kinase 4 - antagonists & inhibitors; Cyclin-Dependent Kinase 6 - antagonists & inhibitors; Cyclin-dependent kinases; Disease control; ErbB-2 protein; Female; Humans; Kinases; Medicine; Medicine & Public Health; Metastases; Middle Aged; Oncology; Original Article; Patients; Progression-Free Survival; Protein Kinase Inhibitors - therapeutic use; Purines - therapeutic use; Receptor, ErbB-2 - metabolism; Retrospective Studies; Statistical analysis; Surgical Oncology; Survival; HER2-low; Breast cancer; HER2-zero; CDK 4/6 inhibitor

Aims and objectives Human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) is a new entity considered a biologically distinct subtype from HER2-zero BC. However, the importance of HER2 low expression on the activity of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) remains unclear....